Skip to main content

Table 3 Initial treatment efficacy and long-term therapeutic data

From: Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review

  Initial treatment efficacy Treatment received after leaving the ICU
  n = 20 n = 18
   At 3 months At 1 year At 2 years
Treatment n Efficacy n (%) n (%) n (%)
Corticosteroids alone 20 10 (50%) 4/18 (22%) 3/18 (17%) 3/13 (23%)
IVIgs 6 1 (17%) 1/18 (5%) 0 0
Cyclosporine 3 1 (33%) 3/18 (17%) 2/18 (11%) 0
Anakinra (IL1Ra) 5 4 (80%) 10/18 (56%) 7/18 (39%) 3/13 (23%)
Etoposide 3 2 (67%) 0 0 0
Methotrexate   5/18 (28%) 5/18 (28%) 4/13 (31%)
Leflunomide 1/18 (5%) 0 0
TNF-α blockers   1/18 (5%) 1/18 (5%) 1/13 (7%)
Cyclophosphamide 0 1/18 (5%) 1/13 (7%)
Azathioprine   0 1/18 (5%) 1/13 (7%)
Tocilizumab (anti-IL6) 0 1/18 (5%) 0
Remission off treatment 0 2/18 (5%) 3/13 (23%)
  1. ICU intensive care unit, IL1Ra interleukin-1 receptor antagonist, IVIgs intravenous immunoglobulins, TNF tumour necrosis factor